Weekly docetaxel in the treatment of elderly patients will advanced nonsmall cell lung carcinoma: A Minnie Pearl Cancer Research Network Phase II Trial

Cancer

Volumn 89, Issue 2, 2000, Pages 328-333

  Hainsworth, John D ^a,b   Burris III, Howard A ^a,b   Litchy, Sharlene ^a   Morrissey, Lisa H ^a   Barton, John H ^b   Bradof, James E ^c   Greco, F Anthony ^a,b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

^c Upstate Carolina CCOP   (United States)

Author keywords

Elderly patients; Nonsmall cell lung carcinoma; Single agent chemotherapy; Weekly docetaxel

Indexed keywords

DOCETAXEL; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; PACLITAXEL; SURVIVAL ANALYSIS; TAXOIDS;

EID: 0034661693     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000715)89:2<328::AID-CNCR17>3.0.CO;2-F     Document Type: Article

References (23)